Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Pear Therapeutics, Inc. (Nasdaq: PEAR), a leader in developing prescription digital therapeutics (PDTs), announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14-16, 2023, in Snowbird, UT. Pear's management will engage in virtual 1x1 meetings during the event. As the first company to receive FDA marketing authorization for PDTs, Pear's products include reSET® for substance use disorder, reSET-O® for opioid use disorder, and Somryst® for chronic insomnia. Pear focuses on innovative, clinically validated software-based medicines to improve patient outcomes and reduce costs for payers.

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14 - 16, 2023 in Snowbird, UT. Pear management will participate virtually in 1x1 meetings at the conference.

BTIG hosted events are intended for prospective and existing BTIG clients only. To request a meeting with Pear management, please contact your BTIG representative to express interest.

About Pear Therapeutics

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET^®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O^®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst^® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005094/en/

Media and Investors:

Meara Murphy

Senior Director, Corporate Communications

meara.murphy@peartherapeutics.com

Source: Pear Therapeutics, Inc.

FAQ

What event is Pear Therapeutics attending in February 2023?

Pear Therapeutics will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14-16, 2023.

How can I request a meeting with Pear Therapeutics at the BTIG conference?

To request a meeting with Pear management, contact your BTIG representative to express interest.

What are some key products of Pear Therapeutics?

Key products include reSET® for substance use disorder, reSET-O® for opioid use disorder, and Somryst® for chronic insomnia.

What is the stock symbol for Pear Therapeutics?

The stock symbol for Pear Therapeutics is PEAR.

What distinguishes Pear Therapeutics in the digital therapeutics market?

Pear Therapeutics is the leader in developing PDTs, being the first to receive FDA marketing authorization for three products.